Abstract 323P
Background
An immune checkpoint inhibitor that targets programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) has recently been discovered, and it demonstrates superior treatment efficacy and improves prognosis over existing chemotherapeutic agents in non-small cell lung cancer. Several studies have demonstrated correlations between computed tomography (CT) imaging features and PD-L1 expression in lung adenocarcinoma (ADC). However, there have been few studies on the association between lung squamous cell carcinoma (SCC) and CT findings. Thus, we aimed to identify the associations between CT findings and PD-L1 expression in SCC and to develop models to predict the expression of PD-L1 in lung SCC using CT.
Methods
This retrospective study included 99 patients diagnosed with SCC and pretreatment CT images and PD-L1 expression assay results. We performed CT feature analysis of the tumors using pretreatment CT images. We then constructed multiple logistic regression models to predict PD-L1 positivity in the total patient group and in 41 advanced-stage (≥ stage IIIB) patients. To identify predictive efficiency, areas under the receiver operating characteristic curves (AUCs) of each model were calculated.
Results
Among the 99 patients, 68 (68.7%) were PD-L1-positive and among the 41 advanced patients, 30 (73.2%) were PD-L1-positive. For the total patient group, the AUC of the ‘total significant features model’ (tumor stage, primary tumor size, pleural nodularity and lung metastasis) was 0.637, and that of the ‘selected feature model’ (pleural nodularity) was 0.556. For advanced-stage patients, the AUC of the selected feature model (primary tumor size, central distribution, pleural nodularity, and pulmonary oligometastases) was 0.882. Among these factors, the presence of pleural nodularity and pulmonary oligometastases had high odds ratios (4.11 and 9.60, respectively).
Conclusions
Our model was able to predict PD-L1 expression in patients with advanced-stage SCC of the lung, and the presence of pleural nodularity and pulmonary oligometastases were notable predictive CT features of PD-L1. A predictive model based on CT features may facilitate non-invasive assessment of PD-L1 expression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported by a VHS Medical Center Research Grant, Republic of Korea (grant number: VHSMC 21007).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
385P - Efficacy and safety of pyrotinib in untreated, advanced non-small cell lung cancer with HER2 mutations: A parallel, multi-center, multi-cohort patient-centric study (CTONG1702 and 1705)
Presenter: Si-Yang Liu
Session: Poster viewing 05.
386P - Efficacy of anlotinib in posterior line treatment of locally advanced and metastatic NSCLC with KRAS mutation
Presenter: Xin Li
Session: Poster viewing 05.
387P - Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study
Presenter: Hidehito Horinouchi
Session: Poster viewing 05.
388P - Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study
Presenter: Yi-Long Wu
Session: Poster viewing 05.
389P - Updated efficacy and safety of pralsetinib in Chinese patients with advanced RET fusion+ non-small cell lung cancer
Presenter: Zhou Qing
Session: Poster viewing 05.
390P - Entrectinib in Japanese patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours
Presenter: Haruyasu Murakami
Session: Poster viewing 05.
391P - Demographics, treatment patterns and clinical outcomes in ROS1-positive non-small cell lung cancer: A referral tertiary cancer centre experience from a low-middle income country
Presenter: Goutam Panda
Session: Poster viewing 05.
392P - A phase II study of SAF-189s in patients with advanced ROS1 fusion-positive non-small cell lung cancer
Presenter: Jinji Yang
Session: Poster viewing 05.
394P - Research of the algorithm for rare driver genes in non-small cell lung cancer using pathological images and artificial intelligence
Presenter: Kiyotaka Yoh
Session: Poster viewing 05.
395P - Molecular landscape of Indian NSCLC: Is NGS the answer?
Presenter: Ullas Batra
Session: Poster viewing 05.